Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Sawinsky

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
International Journal of Clinical Pharmacology and Biopharmacy|October 1, 1976
Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosisJ P Radó, I Sawinsky, E Juhos
International Journal of Clinical Pharmacology and Biopharmacy|October 1, 1975
Dose-response relations in drug-induced inappropriate secretion of ADH: effects of clofibrate and carbamazepineJ P Radó, E Juhos, I Sawinsky
Oncology|January 1, 1987
Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) StudyS Kerpel-Fronius, F Gyergyay, I Hindy, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
International Journal of Clinical Pharmacology and Biopharmacy|October 1, 1976
Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosisJ P Radó, I Sawinsky, E Juhos
International Journal of Clinical Pharmacology and Biopharmacy|October 1, 1975
Dose-response relations in drug-induced inappropriate secretion of ADH: effects of clofibrate and carbamazepineJ P Radó, E Juhos, I Sawinsky
Oncology|January 1, 1987
Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) StudyS Kerpel-Fronius, F Gyergyay, I Hindy, et al.
Pageof 1